^
    Apply
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (IMA401-101) (NCT05359445)
    Phase 1
    Immatics Biotechnologies GmbH
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    05/19/2022
    Primary completion :
    11/01/2025
    Completion :
    12/01/2029
    MAGEA4
    |
    MAGEA4 expression • MAGEA4 overexpression
    |
    Keytruda (pembrolizumab) • IMA401
    ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (NCT05601752)
    Phase 2
    Adaptimmune
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/26/2023
    Primary completion :
    08/12/2026
    Completion :
    08/12/2026
    HLA-A • BRCA • PARP1 • MAGEA4
    |
    HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
    |
    Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    SPEARHEAD-3 Pediatric Study (NCT05642455)
    Phase 1/2
    Adaptimmune
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    09/01/2023
    Primary completion :
    10/01/2026
    Completion :
    07/30/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD-1) (NCT04044768)
    Phase 2
    Adaptimmune
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    08/13/2019
    Primary completion :
    10/10/2021
    Completion :
    04/01/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859)
    Phase 1
    Adaptimmune
    Recruiting
    Last update posted :
    02/16/2024
    Initiation :
    08/20/2019
    Primary completion :
    12/23/2025
    Completion :
    04/30/2037
    HLA-A • MAGEA4
    |
    HLA-A*02 • MAGEA4 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)
    MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922)
    Phase 1
    Adaptimmune
    Active, not recruiting
    Last update posted :
    01/22/2024
    Initiation :
    05/15/2017
    Primary completion :
    12/27/2022
    Completion :
    09/01/2032
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive
    |
    Tecelra (afamitresgene autoleucel)
    Administration of Donor MultiTAA-Specific T Cells for ALL (STELLA) (NCT02475707)
    Phase 1
    Baylor College of Medicine
    Active, not recruiting
    Last update posted :
    10/26/2023
    Initiation :
    02/01/2016
    Primary completion :
    10/29/2019
    Completion :
    10/01/2024
    CD8 • CD4 • MME
    |
    MultiTAA T cell therapy
    Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (PDC-LUNG-101) (NCT03970746)
    Phase 1/2
    PDC*line Pharma SAS
    Active, not recruiting
    Last update posted :
    10/24/2023
    Initiation :
    09/10/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CD8 • HLA-A
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • pemetrexed • PDC*lung
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (NCT02494167)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    06/19/2023
    Initiation :
    02/01/2016
    Primary completion :
    04/01/2024
    Completion :
    02/01/2026
    KIT • WT1 • CD33 • ANPEP
    |
    MultiTAA T cell therapy
    KSH01-TCRT Solid Tumors (NCT05539833)
    Phase 1
    TCRx Therapeutics Co.Ltd
    Recruiting
    Last update posted :
    04/03/2023
    Initiation :
    08/19/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2027
    HLA-A
    |
    HLA-A*02 • HLA-A2 positive
    |
    KSH01
    SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer ( SPEARHEAD-2) (NCT04408898)
    Phase 2
    Adaptimmune
    Withdrawn
    Last update posted :
    11/16/2021
    Initiation :
    07/02/2020
    Primary completion :
    12/01/2021
    Completion :
    12/01/2021
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Keytruda (pembrolizumab) • Tecelra (afamitresgene autoleucel)
    Investigator Initiated Phase 1 Study of TBI-1201 (NCT02096614)
    Phase 1
    Mie University
    Completed
    Last update posted :
    06/18/2021
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2021
    Completion :
    03/01/2021
    MAGEA4
    |
    MAGEA4 expression • HLA-A*24
    |
    cyclophosphamide • fludarabine IV • TBI 1201 • cyclophosphamide intravenous